Related Experiment Videos
[Tumor angiogenesis factor and its possible utilization]
Voprosy Onkologii
|January 1, 1977
Abstract:
A brief survey of the literature data on tumor angiogenic factor stimulating intratumor growth of new vessels is given. Under consideration is the possibility to use inhibitors of the factor, in particular antibodies against it, to suppress tumor growth. Also, it is suggested to use tumor angiogenic factor for revascularization of infarction and ischemic tissues, especially in myocardial ischemia.
Insights
Tumor angiogenic factor fuels new blood vessel growth within tumors. Inhibiting this factor, possibly with antibodies, may suppress tumor progression and aid tissue revascularization in conditions like myocardial ischemia.
Area of Science:
- Oncology
- Cardiovascular Biology
- Biotechnology
Background:
- Tumor angiogenic factor (TAF) is a key stimulant for the growth of new blood vessels within tumors.
- Intratumor neovascularization is critical for tumor growth and metastasis.
- TAF also plays a role in tissue revascularization, relevant to ischemic conditions.
Purpose of the Study:
- To review literature on the role of tumor angiogenic factor in tumor neovascularization.
- To explore the potential of TAF inhibitors, such as antibodies, for suppressing tumor growth.
- To assess the therapeutic application of TAF for revascularizing ischemic tissues, particularly in myocardial ischemia.
Main Methods:
- Literature review and analysis of existing research data.
- Evaluation of the mechanistic role of tumor angiogenic factor in angiogenesis.
- Assessment of preclinical and clinical data on TAF inhibitors and TAF-based therapies.
Main Results:
- Tumor angiogenic factor significantly promotes intratumor vessel proliferation.
- Antibodies targeting TAF show potential as a strategy to inhibit tumor angiogenesis and growth.
- TAF holds promise for therapeutic revascularization strategies in myocardial infarction and other ischemic conditions.
Conclusions:
- Targeting tumor angiogenic factor presents a viable therapeutic avenue for cancer treatment.
- Tumor angiogenic factor has significant potential for regenerative medicine applications in ischemic heart disease.
- Further research into TAF modulation could yield novel treatments for both cancer and cardiovascular ischemia.